A human insulin-like growth factor (IGF) binding protein stock solution and method of making the same include a non-recombinant human IGF binding protein-3 (nr-IGFBP-3) in an aqueous buffered medium. The concentration of the nr-IGFBP-3 in the stock solution ranges from about 16 micrograms per milliliter (g/ml) to about 40 g/ml. A kit includes a set of calibrators for nr-IGFBP-3. The set of calibrators includes the nr-IGFBP-3 in different concentrations.

In one embodiment, a method includes, by each of one or more network nodes of a multi-hop wireless network that are configured as initiators: receiving from a central controller an address of a particular network node that is configured as a responder. Using the address and by adjusting beamforming weights, the initiator may transmit a message to establish a wireless connection with a particular network node that is configured as a responder. Each responder may adjust its beamforming to receive a message from one of the initiators addressed to the responder to establish a wireless connection with the responder. When the responder receives the message from the initiator addressed to the responder, the responder may respond to the initiator to establish a wireless connection with the initiator.

This invention provides synthetic immodulin peptides and related compositions and methods. The peptides of this invention exhibit new and surprising biological activities, such as the expansion of specified differentiated mammalian lineages from precursor cell populations which play important roles in post-apoptotic clearance, autoimmunity, targeted vaccination, cancer and trauma, by contacting mammalian cells with the synthetic peptides. Furthermore, the peptides of the invention can be made significantly more potent by each of a series of modifications described in the invention, including a carboxyterminal tripeptide extension to the canonical immodulin core sequence, other peptide extensions with kinase-inhibiting and other domains, substitution with modified amino acids, conjugation to certain bioactive small molecules, complexation to metals or glycosaminoglycans, and co-administration with helper molecules. The invention also teaches compositions and methods for enhancing previously disclosed uses of immodulin peptides to boost the efficacy of immodulin peptides in trauma, immune imbalance, cancer and other medically relevant conditions.

The present disclosure relates to treatment of subpopulation of neonates for reducing the risk of IVH and/or severe IVH, such as grade 3 or 4 IVH by administering a therapeutic amount of a composition comprising IGF-1 and an IGF binding protein (such as IGFBP-3), for example as a complex, at a dose of 200-500 g/Kg/day. In a further aspect there is provided stabilisation of vital functions when hyperosmolarity occurs and/or protection from circulatory collapse.